Javascript must be enabled to continue!
Autoantibodies to mitochondrial 2-oxo-acid dehydrogenase complexes in localized scleroderma
View through CrossRef
Abstract
Sera from patients with localized scleroderma frequently produce cytoplasmic staining by indirect immunofluorescence, although the antigen remains to be determined. We studied the prevalence, antigen specificity and associated clinical characteristics of anti-cytoplasmic antibodies in localized scleroderma. Serum samples from 60 patients with localized scleroderma were examined by indirect immunofluorescence analysis and immunoblotting. By immunofluorescence analysis on HEp-2 cell substrate, seven of 60 (12%) patients were shown to be positive for anti-cytoplasmic antibodies. Among these, six patients with generalized morphea had anti-mitochondrial antibodies as shown by immunoblotting: they showed reactivity with the E2 component of pyruvate dehydrogenase complex (PDC), with protein X, and with the E2 component of α-oxo-glutarate dehydrogenase complex, while two of them showed reactivity with PDC-E1α. One of these patients who was positive for anti-PDC-E1α antibody showed laboratory abnormalities, suggesting the presence of primary biliary cirrhosis. The age of disease onset was significantly higher in these six patients than in those without anti-mitochondrial antibodies. Furthermore, five of them were classified into generalized morphea with multiple plaque lesions but without linear lesions (multiple plaque type). These observations suggest that major antigens for anti-cytoplasmic antibodies in patients with localized scleroderma are mitochondrial enzymes, 2-oxo-acid dehydrogenase complexes. Patients with anti-mitochondrial antibodies may comprise a unique subset of localized scleroderma designated multiple plaque type of generalized morphea of older onset.
Oxford University Press (OUP)
Title: Autoantibodies to mitochondrial 2-oxo-acid dehydrogenase complexes in localized scleroderma
Description:
Abstract
Sera from patients with localized scleroderma frequently produce cytoplasmic staining by indirect immunofluorescence, although the antigen remains to be determined.
We studied the prevalence, antigen specificity and associated clinical characteristics of anti-cytoplasmic antibodies in localized scleroderma.
Serum samples from 60 patients with localized scleroderma were examined by indirect immunofluorescence analysis and immunoblotting.
By immunofluorescence analysis on HEp-2 cell substrate, seven of 60 (12%) patients were shown to be positive for anti-cytoplasmic antibodies.
Among these, six patients with generalized morphea had anti-mitochondrial antibodies as shown by immunoblotting: they showed reactivity with the E2 component of pyruvate dehydrogenase complex (PDC), with protein X, and with the E2 component of α-oxo-glutarate dehydrogenase complex, while two of them showed reactivity with PDC-E1α.
One of these patients who was positive for anti-PDC-E1α antibody showed laboratory abnormalities, suggesting the presence of primary biliary cirrhosis.
The age of disease onset was significantly higher in these six patients than in those without anti-mitochondrial antibodies.
Furthermore, five of them were classified into generalized morphea with multiple plaque lesions but without linear lesions (multiple plaque type).
These observations suggest that major antigens for anti-cytoplasmic antibodies in patients with localized scleroderma are mitochondrial enzymes, 2-oxo-acid dehydrogenase complexes.
Patients with anti-mitochondrial antibodies may comprise a unique subset of localized scleroderma designated multiple plaque type of generalized morphea of older onset.
Related Results
Abstract IA22: Autoimmune rheumatic diseases and cancer
Abstract IA22: Autoimmune rheumatic diseases and cancer
Abstract
Some rheumatic disease autoantibodies are powerful markers of subgroups of patients who have distinct disease phenotypes and trajectories. Of particular int...
Autoantibodies predict type 1 diabetes after gestational diabetes – a 23-year cohort study
Autoantibodies predict type 1 diabetes after gestational diabetes – a 23-year cohort study
ObjectiveTo study the predictive value of autoantibodies for type 1 (T1DM) and type 2 (T2DM) diabetes morbidity after gestational diabetes (GDM) in a 23-year follow-up study.Design...
Vitamin D and Vitamin D Receptor in Scleroderma Subtypes
Vitamin D and Vitamin D Receptor in Scleroderma Subtypes
Vitamin D Receptor (VDR) is a member of the nuclear hormone receptor family. 1,25(OH)2D, a form of metabolically active vitamin D3 form, is the ligand of VDR. When VDR and 1,25(OH)...
Autoantibodies in Scleroderma
Autoantibodies in Scleroderma
AbstractAutoantibodies directed against nuclear, nucleolar, and a number of cytoplasmic components are described in the sera of scleroderma patients. Early studies of autoantibodie...
The Origin of Relative Stability of Di-µ-oxo M–M Chiral Salen Complexes [M–M = Ti(IV)–Ti(IV), V(IV)–V(IV), Cr(IV)–Cr(IV), and Mn(IV)–Mn(IV)]: A Quantum-Chemical Analysis
The Origin of Relative Stability of Di-µ-oxo M–M Chiral Salen Complexes [M–M = Ti(IV)–Ti(IV), V(IV)–V(IV), Cr(IV)–Cr(IV), and Mn(IV)–Mn(IV)]: A Quantum-Chemical Analysis
Abstract
Di-µ-oxo dimetal cores can form dinuclear complexes with definite stereochemistries. Recent studies describing the synthesis and evaluation of titanium(IV) ...
Mitochondria Fusion and Fission
Mitochondria Fusion and Fission
Abstract
Mitochondrial structural dynamics is regulated by the fusion or fission of these organelles. Recently published evidence indicates the ...
Ionic complexes of biodegradable polyelectrolytes
Ionic complexes of biodegradable polyelectrolytes
Biopolymers are polymers produced by living organisms. A more broad classification would embrace also those polymers synthesized from renewable sources which are able to display bi...
OR23-05 Acquired Osteomalacia Associated with Autoantibodies against PHEX
OR23-05 Acquired Osteomalacia Associated with Autoantibodies against PHEX
Abstract
Disclosure: Y. Hoshino: None. K. Okamoto: None. K. Hajime: None. K. Irie: None. S. Kimura: None. N. Hidaka: None. D. Hagiwara: None. M. Nangaku: Dr. Nang...

